AT291247B - Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen - Google Patents

Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen

Info

Publication number
AT291247B
AT291247B AT768868A AT768868A AT291247B AT 291247 B AT291247 B AT 291247B AT 768868 A AT768868 A AT 768868A AT 768868 A AT768868 A AT 768868A AT 291247 B AT291247 B AT 291247B
Authority
AT
Austria
Prior art keywords
pyrazin
imidazo
ones
preparation
new
Prior art date
Application number
AT768868A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of AT291247B publication Critical patent/AT291247B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT768868A 1967-08-08 1968-08-06 Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen AT291247B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65904267A 1967-08-08 1967-08-08
US72803368A 1968-05-09 1968-05-09

Publications (1)

Publication Number Publication Date
AT291247B true AT291247B (de) 1971-07-12

Family

ID=27097746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT768868A AT291247B (de) 1967-08-08 1968-08-06 Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen

Country Status (11)

Country Link
US (1) US3507866A (de)
AT (1) AT291247B (de)
BE (1) BE719154A (de)
CH (1) CH516574A (de)
DE (1) DE1795062A1 (de)
DK (1) DK123484B (de)
ES (1) ES356976A1 (de)
FR (2) FR1578366A (de)
GB (1) GB1193035A (de)
IL (1) IL30463A0 (de)
NL (1) NL6810650A (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) * 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7923041B2 (en) * 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
SI2069352T1 (sl) * 2006-08-02 2013-12-31 Cytokinetics, Inc. Določene kemijske entitete, sestavki in postopki
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CN102993204A (zh) 2006-08-02 2013-03-27 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
MX337906B (es) * 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
US7851484B2 (en) * 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CN102686225A (zh) * 2009-10-26 2012-09-19 西格诺药品有限公司 杂芳基化合物的合成和纯化方法
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
IN2014DN00200A (de) 2011-07-13 2015-06-05 Cytokinetics Inc
SG10201912850WA (en) 2011-10-19 2020-02-27 Signal Pharm Llc Treatment Of Cancer With TOR Kinase Inhibitors
WO2013082344A1 (en) 2011-12-02 2013-06-06 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
MX358303B (es) 2012-02-24 2018-08-14 Signal Pharm Llc Uso de 7-(6-(2-hidroxipropan-2il) piridin-3-il)-1-((1r,4r)4-metoxi ciclohexil)-3, 4-dihidropirazin-[2,3-b] pirazin-2(1h)-ona o una sal, estereoisómero o tautómero aceptable farmaceuticamente del mismo, en combinación con una cantidad efectiva de erlotinib o azacitidina para preparar un composición farmacéutica en el tratamiento de cáncer de pulmón de cédula no pequeña, avanzado.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP6392242B2 (ja) 2012-12-17 2018-09-19 パリオン・サイエンシィズ・インコーポレーテッド 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
AU2014207641A1 (en) 2013-01-16 2015-08-06 Signal Pharmaceuticals, Llc Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith
MX2015014455A (es) 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
EP2986609B1 (de) 2013-04-17 2019-06-19 Signal Pharmaceuticals, LLC Pharmazeutische formulierungen, verfahren, feste formen und verfahren zur verwendung von 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)-pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-on
BR112015026292B1 (pt) 2013-04-17 2022-04-12 Signal Pharmaceuticals, Llc Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
NZ631082A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EA030808B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
US9474757B2 (en) 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EP3131552B1 (de) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Verfahren zur behandlung von krebs anhand einer tor-kinasehemmerkombinationstherapie
EP3131551A4 (de) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC Feste formen mit 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-on und co-former, zusammensetzungen und verfahren zu deren verwendung
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
MX2019015731A (es) 2017-06-22 2020-08-03 Celgene Corp Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.

Also Published As

Publication number Publication date
ES356976A1 (es) 1970-10-16
BE719154A (de) 1969-02-07
IL30463A0 (en) 1968-09-26
DK123484B (da) 1972-06-26
US3507866A (en) 1970-04-21
DE1795062A1 (de) 1972-03-30
CH516574A (de) 1971-12-15
NL6810650A (de) 1969-02-11
FR8409M (de) 1971-03-31
FR1578366A (de) 1969-08-14
GB1193035A (en) 1970-05-28

Similar Documents

Publication Publication Date Title
AT291247B (de) Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen
CH505118A (de) Verfahren zur Herstellung von 1,2,4-Triazin-5-onen
AT275521B (de) Verfahren zur Herstellung von neuen 1,4-Dihydropyridinderivaten
CH481110A (de) Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen
CH502364A (de) Verfahren zur Herstellung von neuen 1,2,4-Oxadiazolen
AT281836B (de) Verfahren zur Herstellung von neuen 2-Methyl-3-carbonsäureamido-chinoxalin-di-N-oxiden-(1,4)
AT277221B (de) Verfahren zur Herstellung von neuen 5-Nitro-2-furyl-2-isoxazolin-derivaten
CH496022A (de) Verfahren zur Herstellung von neuen N,N'-Diglycidyl-Verbindungen
AT291250B (de) Verfahren zur Herstellung von neuen 5-NR<1>R<2> -6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen
AT277985B (de) Verfahren zur Herstellung von neuen Nitro-furan-, -thiophen- oder -pyrrol-derivaten
CH498132A (de) Verfahren zur Herstellung neuer Pyrido (1,2-a)-s-triazindione
AT284128B (de) Verfahren zur Herstellung von neuen 2-Halogenmethyl-3-carbansäureamido-chinoxalin-di-N-oxiden-(1,4)
AT280271B (de) Verfahren zur Herstellung von neuen Cumarinyl-v-triazoloxydderivaten
AT281838B (de) Verfahren zur Herstellung von neuen 2-Isothiuronium-methyl-3-carbonsäureamido-chinoxalin-di-N-oxid-(1,4)-halogeniden
AT299172B (de) Verfahren zur Herstellung von neuen Naphthylisopropyl-Derivaten
CH489525A (de) Verfahren zur Herstellung von 1,8-Naphthyridinderivaten
AT283356B (de) Verfahren zur Herstellung von neuen 1,2,4-Oxdiazolidin-Derivaten
CH508645A (de) Verfahren zur Herstellung von neuen 5-substituierten y-Carbolinderivaten
CH453370A (de) Verfahren zur Herstellung von neuen 5,6-Dihydro-6-oxo-pyrido (2,3-b)(1,4)benzoxazepinen
AT290026B (de) Verfahren zur Herstellung von neuen 22-Amino-23,24-bisnorcholanderivaten
AT293634B (de) Verfahren zur Herstellung von neuen 17α-Acyloxy-11β-methyl-19-norpregn-4-en-3,20-dionen
CH522619A (de) Verfahren zur Herstellung von neuen Derivaten von 2a,3a-Epithioandrostanen
AT291967B (de) Verfahren zur Herstellung von neuen N-Phenyl-N-2-fluor-1,1,2,2,-tetrachloräthylsulfenyl-sulfamiden
CH469729A (de) Verfahren zur Herstellung von neuen 4,9-Dihydrothieno-(2,3-b)-benzo-(e)-thiepinderivaten
AT281020B (de) Verfahren zur Herstellung von neuen 3-Imino-1,2-benzisothiazolinen

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee